

Assembly of Radically Recoded *E. coli* Genome Segments

Julie E. Norville^{1,2}, Cameron L. Gardner³, Eduardo Aponte⁴, Conor K. Camplisson^{1,2},
Alexandra Gonzales¹, David K. Barclay¹, Katerina A. Turner¹, Victoria Longe⁵, Maria
Mincheva⁶, Jun Teramoto^{1,7,8}, Kento Tominaga⁹, Ryota Sugimoto¹⁰, James E. DiCarlo¹¹,
Marc Guell², Eriona Hysolli¹, John Aach¹, Christopher J. Gregg¹², Barry L. Wanner¹³,
George M. Church^{1,2*}

¹Department of Genetics, Harvard Medical School, Boston MA 02115, USA

²Wyss Institute for Biologically Inspired Engineering, Harvard University, Cambridge,
MA 02138, USA

³National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of
Health, Bethesda MD 20892, USA and Nuffield Department of Medicine, Medical
Sciences Division, University of Oxford, Headington, Oxford OX3 7BN, UK

⁴bioMerieux, Cambridge, MA 02142, USA

⁵Department of Electrical Engineering and Computer Science, Massachusetts Institute of
Technology, Cambridge, MA 02143, USA

⁶Sofia University, Sofia 1000, Bulgaria

⁷On leave from Department of Biological Sciences, Purdue University, West Lafayette,
IN 47907, USA

⁸Present address: Integrated Research Center of Kobe University, Chuo-ku, Kobe 650-
0047, Japan

⁹Graduate School of Science and Engineering, Tokyo Metropolitan University, 1-1
Minami-Osawa, Hachioji-shi, Tokyo 192-0397, Japan

¹⁰Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo
Institute of Technology, R1-104, 4259 Nagatsutacho, Midori-ku, Yokohama 226-8503,
Japan

¹⁰College of Physicians and Surgeons, Columbia University, New York City, NY 10032,
USA

¹²GreenLight Biosciences, Inc., Medford, MA 02155

¹³Department of Microbiology and Immunobiology, Harvard Medical School, Boston,
MA 02115, USA

*Correspondence to: Email: gchurch@genetics.med.harvard.edu

Abstract

The large potential of radically recoded organisms (RROs) in medicine and industry depends on improved technologies for efficient assembly and testing of recoded genomes for biosafety and functionality. Here we describe a next generation platform for conjugative assembly genome engineering, termed CAGE 2.0, that enables the scarless integration of large synthetically recoded *E. coli* segments at isogenic or adjacent genomic loci. A stable *tdk* dual selective marker is employed to facilitate cyclical assembly and removal of attachment sites used for targeted segment delivery by site-specific recombination. Bypassing the need for vector transformation harnesses the multi-Mbp capacity of CAGE 1.0, while minimizing artifacts associated with RecA-mediated homologous recombination. Our method expands the genome engineering toolkit for radical modification across many organisms and for recombinase-mediated cassette exchange (RMCE).

Introduction

Radically recoded organisms (RROs) are desirable for several reasons. For example, recoding enforces genetic and metabolic isolation (1, 2), allows facile use of non-standard amino acids (1), and has the potential to enable multivirus resistance (3, 4). RROs can be used to produce proteins containing non-standard amino acids and are an enabling tool to build biocontained microbes for environmental remediation, industrial applications, and medicine (5). In addition, *E. coli* can be engineered to stably maintain non-native sequences from other organisms (6-9), enable multiplex modification (10-12), and deliver DNA to other organisms including diverse bacteria, fungi, plants, and mammalian cells (13-17). The ability to deliver scarless large segments of modified DNA to genomes with or without recombination is a desirable feature as genome-scale modifications of organisms across biological kingdoms becomes routine (9, 12, 18-31).

In a separate study, we tested 55 of the 87 50-kb segments required to construct a recoded *E. coli* strain in which seven codons were reassigned to synonymous codons, denoted *rE.coli-57* (5). A transformation-based assembly approach allowed us to evaluate each recoded segment individually for strain viability following deletion of the corresponding chromosomal region. To do this, we created a testing pipeline where synonymous codon replacements can be validated for strain fitness of each segment. The 3.97 MB genome design of *rE.coli-57* has 62,214 codon replacements (5). To construct a single *E. coli* strain containing all 87 segments, we will need to replace multiple segments in a single strain in isogenic locations. Previously, we used Conjugative Assembly Genome Engineering (CAGE 1.0) to merge sets of genome modifications (32) to construct a

Genomically Recoded Organism (GRO) where all instances of the TAG stop codon had been replaced with TAA stop codons (3). Methods that allow replacing natural sequences with synthetic DNA segments offer the potential of nearly limitless genome modifications, provided the recoded sequences are viable within living cells (5).

When constructing organisms with highly modified genome sequence, there are tradeoffs that will determine which genome assembly technique is optimal. One parameter is how much testing of recoded segments is required to generate optimal phenotypes. The requirement to validate strain fitness favors approaches where both sequences are initially maintained to allow partial or complete deletion of the corresponding natural region, to enable identification of deleterious sequences, whereas strain production with validated sequences supports direct replacement. A second factor is the size of the replacement segments, which can differ based on the DNA assembly methodology, the need to test large numbers of DNA segments individually or assemblies of DNA segments, and the method used for delivery of the segments by electroporation, phage packaging, conjugation, or transplantation. A final consideration is the requirement for homologous recombination, which can facilitate particular strain assembly methodologies but can also generate undesirable artifacts. *E. coli* offers the ability of using recombinogenic or non-recombinogenic cells, and both the testing protocol (5) and CAGE 2.0 can benefit from approaches that minimize recombination.

Although our assembly method optimizes delivery of recoded DNA with minimal opportunity for recombination, our testing protocol (5) is not directly amenable to the

assembly of multiple fragments. A challenge is the size of recoded DNA segment that can be delivered. Electroporation can only accommodate segments up to several hundred kb (7). Although it may be useful to test smaller segments, assembling a genome sequentially from small segments will be time-consuming. Therefore a method such as CAGE is ideal (32) because it is amenable to hierarchical assembly. Techniques described herein will make it possible to extend our testing protocol to larger segment assemblies and, if necessary, to combine the segment assembly and testing protocols. Here we introduce a next generation protocol, termed CAGE 2.0, for integrating recoded segments into a single *E. coli* strain. Instead of using *recA*-mediated recombination for hierarchical assembly as done in CAGE 1.0, our protocol uses λ -integrase mediated site-specific recombination for the targeted assembly of recoded segments. Bypassing the need for the large homology regions that are required for homologous recombination mitigates against recombination events that can lead to loss of recoded regions during the assembly process. Thus, CAGE 2.0 provides routes to eliminate undesired recombination, replaces segments isogenically, and can be employed to introduce multiple recoded segments in a single strain (Fig. 1.).

Results

To expand on the capabilities of CAGE 1.0 in genome engineering, we devised CAGE 2.0 to deliver recoded segments by site-specific recombination using phage attachment sites that are flexibly shuffled with minimal recombineering to enable genome assembly. Recoded-DNA segments are delivered using vectors that harbor an F plasmid origin, which in *E. coli* has the capacity to replicate extremely large DNA segments ranging from 600 kb to 2.5 Mb (7, 33, 34).

In the CAGE 2.0 protocol (Fig. 1.), low copy F origin plasmids containing recoded segments are directly conjugated into recipient *E. coli* and site-specifically recombined onto the genome by λ integrase-mediated recombination between the vector *attP* and chromosomal *attB* sites, which are inserted at defined loci by recombineering. Next, the corresponding chromosomal segment is eliminated by λ Red-directed exchange by a chloramphenicol resistance cassette. The resultant strain is then modified for subsequent use as a recipient by removal of residual vector sequences and *att* sites flanking the recoded segment in two sequential steps using MAGE (10) and *E. coli* thymidine kinase (*tdk*) as a dual selectable marker (35). Finally, the host is set for introduction of a new segment by introduction of a new *tdk-attB* cassette in the locus where the next recoded segment is to be integrated (Fig. 1.). A novelty of the protocol is the use of *tdk*, a marker that can be used repeatedly in the same strain to assist in either adding or removing elements from genome, allowing for segment assembly.

While developing the testing protocol, we initially attempted to integrate recoded segments both close to and far away from their natural location in *E. coli* K-12 BW38028 (36). In this strain, we found recombination between natural and recoded segment sequences was problematic at the isogenic locus. Accordingly, we chose two precautions in our initial CAGE 2.0 experiment. We elected to assemble two adjacently recoded segments (segments 43R and 47R (5)) in genomic locations greater than 1-Mb apart in order to minimize recombination. We also used the *recA1* host *E. coli* K-12 DH10B-MAGE for subsequent CAGE 2.0 experiments to minimize recombination (5, 37, 38). By expressing λ integrase during the conjugation process, we were able to recover single-copy recoded-segment integrants from the resulting population of cells. Proceeding directly with these clones, we reset the strain by eliminating the *attL* and *attR* sites created by integration and residual vector sequences (Fig. 1.). Performing this process repeatedly and efficiently required the use of a robust dual selectable marker.

To enable the methodology, we tested an alternative dual-selectable marker, *tdk*, which enables maintenance of a stable selective advantage (analogous to *tolC* (39)) over multiple rounds of selection using commercially available reagents in a single strain (Fig. 2. A, B, and C). We optimized the positive and negative selection conditions of *tdk* for use in GROs (1). We also tested herpes simplex virus thymidine kinase (*hsv-tk*) (40), but found that *E. coli tdk* was more robust over multiple selection rounds. When optimizing the negative selection for *tdk*, we circumvented the use of dP because it is a potent mutagenic reagent (40), and instead used AZT, a chain-terminator that results in failure of cell division at high doses (41) (Fig. 2. A and B; see the Supplement for details.) The

selectable *tdk* is also attractive because it can be used in a wide range of organisms (42, 43). It is also appealing because it can maintain utility in the cell over multiple rounds without requiring extensive strain modifications.

By using *tdk*, we developed a protocol to reset the strain after addition of the recoded segment 47R (5) (Fig. 1.). Initially, we experienced difficulty eliminating the vector backbone, possibly because this region contains the F replication origin. By using MAGE and negative selection of the adjacent *tdk* marker, we were able to delete the backbone region. The region containing the other attachment site was easily removed by swapping with *tdk* and introduction of a new *attB* site. We subsequently integrated segment 43R at the new *attB* site adjacent to 47R.

When we tested growth of the strain containing the adjacent 43R and 47R segments, we found the normalized generation time was significant slower than strains containing either segment alone (Fig. 3. A and B). This result motivated us to consider the importance of context in strain development and re-examine alternative routes to assembly of the recoded segments. As a test case, we chose segment segment 16R (5) for isogenic replacement in a *recAI* host. We first integrated the segment 16R by conjugation/integration on the genome adjacent to the natural segment. In attempts to eliminate the natural segment together with *tdk* and *attL* using MAGE and negative selection, all resulting strains proved to have undergone recombination between the natural and recoded segment. As an alternative, we first removed the natural segment by Red-mediated recombination with a chloramphenicol resistance cassette marker and the

deleted *tdk* together with vector and *attL* sequences using MAGE. Subsequent removal of *attR* site with the *tdk* selection was then successful. Thereby, our protocol allows the removal of adjacent *att* sites, vector sequences, and other markers for scarless replacements at an isogenic location. Analysis of the growth curve of the segment 16R isogenic replacement revealed a growth rate similar to the parental wild-type strain, suggesting isogenic replacements that preserve the genome context of the segment are useful intermediates for subsequent assemblies (Fig. 3. C). The integration of recoded segments at natural loci is a key consideration for optimizing strain phenotypes and will eventually be a prerequisite for fully isogenic construction of *rE.coli-57*.

Discussion

The prospect of whole genome reconstruction for RROs is increasingly becoming realized. The ability to synthesize and assemble large segments of recoded genomic DNA and deliver them to target loci in host organisms is continuing to evolve as technologies for genetic manipulations and large-scale DNA synthesis advance. One primary obstacle that impedes progress is genetic recombination between the natural and recoded sequences after delivery into host strains. As we demonstrated in our testing pipeline, one way to circumvent this problem is to retain the recoded segment in a plasmid-borne vector form and to delete the corresponding natural segment from the host chromosome prior to integration. Combining this order of operations with CAGE 2.0 may provide a facile route to generate isogenic replacements. As shown previously (5), this approach may require use of Cas9 in an additional step to eliminate the episomal delivery vector following integration recoded segment. We also have a protocol for elimination of the Cas9 plasmid (see Supplement). As we move towards generation of *rE.coli-57*, hierarchical methods of assembly will dramatically reduce the time to final strain construction compared to sequential addition of 87 segments. For hierarchical assembly using CAGE 2.0, the protocol must support the excision, maintenance, transfer, and integration of increasingly large recoded genome segments. Currently, we can do this for as many as 8 segments, drastically reducing the number of steps required for hierarchical assembly.

An alternative to large vectors required for CAGE 2.0 would be development of a conjugation-based RMCE method, where very large recoded genome regions flanked by

orthogonal *attP* sites are transferred from donor to recipient strains and inserted at isogenic loci by conjugal integration. This method takes advantage of well-characterized attachment sites commercially utilized in Gateway products, which are capable of unidirectional integration. With CAGE 2.0, many tools for the task have been prototyped, such as *tdk* insertion and removal of recombinase sites, integration that is simultaneous with conjugation, strong markers that select for conjugated DNA and recipient strains. A potential hurdle to overcome in developing this combined approach is the possibility of undesired recombination observed previously using RMCE in *E. coli* (28). An ideal host strain for RMCE + CAGE 2.0 would exhibit a low frequency of unwanted recombination, favoring predictable and selectable isogenic replacements.

Performing CAGE 2.0 in non *E. coli* organisms where maintenance of recombination is essential or where each modification is time consuming will provide a greater challenge. Deleting the segment before integration is probably necessitated in this approach for isogenic replacements. If double crossovers can be minimized, then a background that enables recombination could potentially offer some advantages for hard-to-modify strains, possibly allowing an approach where one partially deletes the wild-type sequence but leaves homology arms on either side. One could then select or screen for integration with some markers (i.e., a thymidine kinase on either side or fluorescent markers), followed by a selection or screen for removal of those markers. Potentially this offers a route for an automated approach to strain reset utilizing endogenous recombination pathways, which would be desirable in hard to modify strains such as mammalian cells, where advance deletion of one chromosomal fragment using CRISPR (44, 45) may not

be disruptive to the cell and where bacterial artificial chromosome (BAC) libraries provide an engineerable substrate that contains large homologous regions.

As one begins to modify BACs for GP-Write and deliver them to mammalian cells or other organisms, the CAGE 2.0 protocol may be directly useful in a number of ways. Conjugal integration provides a route to reduce BAC vectors previously utilized for genome sequencing to single copy and proceed with either MAGE modification or replacement of synthesized regions assisted by positive and negative *tdk* selections, within a strain suitable for BAC maintenance (38).

After modification these vectors can be excised or potentially transferred to other strains as genome integrants using RP4 conjugation (15). If necessary, several vectors can be assembled together using the same protocol prior to transfer to another strain. The ability to modify and transfer BAC vectors and genomes into mammalian cells and other organisms from biocontained *E. coli* (1) is even more advantageous, offering a method that will minimize contamination.

Overall, our results highlight potential opportunities and challenges of recoded genome assembly (Fig. 4.). Both for these protocols and as one moves towards conjugation and integrase assisted genome engineering in *E. coli*, it will be desirable to minimize recombination proficiency, which may allow automation of the protocol. Recently, we have utilized Cas9 to eliminate strains that exhibit undesired mutations (46). Overall, we have generated a new set of tools helpful to extend testing protocols (43) and are

developing RMCE + CAGE 2.0 to facilitate assembly of multiple segments and enhance hierarchical approaches.

Acknowledgments

This research was supported by Department of Energy grant DE-FG02-02ER63445 to G.M.C., Synthetic Biology Engineering Research Center from the National Science Foundation SA5283-11210 to G.M.C, DARPA contract HR0011-13-1-0002 to G.M.C, NSF grant number 106394 to B. L. W., Summer Honors Undergraduate Research Program Grant to E.A., and Origins Summer Undergraduate Research Grant to M.M.




Figure 1. Strategy for CAGE 2.0. **Conjugal λ Integration** of the vector into the recipient strain at single copy. The recipient strain contains the dual selective marker *E. coli* thymidine kinase (*tdk*) and λ integrase *attB* site to the right of the chromosomal sequence that will be replaced. **λ Red Deletion** of chromosomal sequence corresponding to the recoded segment using a chloramphenicol cassette (*cat*). **λ Red Reset Step:** The regions surrounding the recoded segment are removed using *tdk* cassettes and MAGE oligos. **λ Red Setup Step:** To prepare for addition of an additional segment, a cassette containing *tdk* and *attB* is added to the chromosome.




Figure 2. Repetitive *tdk* selection and counterselection maintains a stable selective advantage over multiple cycles (A, B, and C). A) Using a selection reagent FDU utilized for herpes simplex virus thymidine kinase (*HSV-tk*) (40), but replacing the mutagenic counterselection reagent dP (6-(β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one) with the chain terminator AZT, we developed selection and counterselection conditions for *tdk* using commercially available reagents. B) Selection Mechanism of Action: Tdk rescues strains in the presence of FDU, which blocks thymidine salvage. Counterselection Mechanism of Action: The presence of *tdk* allows AZT, a chain terminator that inhibits DNA synthesis, to be incorporated into DNA after phosphorylation with *tdk* (47, 48). C) To test the robustness of reuse of the *E. coli* thymidine kinase gene over multiple cycles in the same strain, we tested the maintenance

of the strain to selective advantage during co-transformation with a set of MAGE oligos designed to implement modifications over 10 genomic locations.




Figure 3. Phenotypic analysis of adjacent and sequential recoded segments. A) Phenotype established by transformation of recoded segment vector and deletion of the corresponding wild type region (43). B) Phenotype established by iterative assembly of two segments at a non-natural location. C) Phenotype established for an isogenic segment replacement.

Method	Scale	Advantages
Testing pipeline protocol extended with this work.	<ul style="list-style-type: none"> -<u>at most 1-6 segments</u> -electroporation is the limiting factor -preventing RecA recombination would be advantageous 	<ul style="list-style-type: none"> -do not need to clean up strain markers from strain where segment is extracted
CAGE 2.0 (excision of segments as vectors and delivery by conjugation and single site recombination) as described in this work.	<ul style="list-style-type: none"> -<u>at least 1-8 segments</u> -F vector capacity may allow up to 2 Mb -conjugation is a genome scale technology -excision tested in this work for 8 segment genomic region -selection of additional markers on segment vector may assist in conjugation and maintenance of larger segments -preventing RecA recombination would be advantageous 	<ul style="list-style-type: none"> -useful for testing segments in natural context -may be useful for direct capture of large segments -directly compatible with testing pipeline methodology (deletions of chromosomal regions to identify problematic regions)
RMCE + CAGE 2.0 (delivery of conjugated genome and two site recombination)	<ul style="list-style-type: none"> -<u>theoretically a genome-scale technology</u> -preventing RecA recombination is required 	<ul style="list-style-type: none"> -theoretically enables hierarchical assembly and more rapid strain construction -ideal option if RecA1 problem can be solved -two site unidirectional integration validated by Gateway
CAGE (1.0)	<ul style="list-style-type: none"> -<u>a genome scale technology</u> -a RecA+ background is required increasing risk of double crossovers 	<ul style="list-style-type: none"> -enables hierarchical assembly -already validated

Figure 4. Survey of methodologies for assembling radically recoded genomes

References

1. D. J. Mandell *et al.*, Biocontainment of genetically modified organisms by synthetic protein design. *Nature* **518**, 55-60 (2015).
2. N. J. Ma, F. J. Isaacs, Genomic Recoding Broadly Obstructs the Propagation of Horizontally Transferred Genetic Elements. *Cell Syst*, (2016).
3. M. J. Lajoie *et al.*, Genomically recoded organisms expand biological functions. *Science* **342**, 357-360 (2013).
4. M. J. Hammerling *et al.*, Bacteriophages use an expanded genetic code on evolutionary paths to higher fitness. *Nat Chem Biol* **10**, 178-180 (2014).
5. N. Ostrov *et al.*, Design, Synthesis and Testing Towards a 57-Codon Genome. *Science*, (2016).
6. M. O'Connor, M. Peifer, W. Bender, Construction of large DNA segments in *Escherichia coli*. *Science* **244**, 1307-1312 (1989).
7. H. Shizuya *et al.*, Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in *Escherichia coli* using an F-factor-based vector. *Proc.Natl.Acad.Sci.USA* **89**, 8794-8797 (1992).
8. Y. Sheng, V. Mancino, B. Birren, Transformation of *Escherichia coli* with large DNA molecules by electroporation. *Nucleic Acids Res.* **23**, 1990-1996 (1995).
9. J. Song, J. M. Bradeen, S. K. Naess, J. P. Helgeson, J. Jiang, BIBAC and TAC clones containing potato genomic DNA fragments larger than 100 kb are not stable in *Agrobacterium*. *Theor Appl Genet* **107**, 958-964 (2003).
10. H. H. Wang *et al.*, Programming cells by multiplex genome engineering and accelerated evolution. *Nature* **460**, 894-898 (2009).
11. H. H. Wang *et al.*, Genome-scale promoter engineering by coselection MAGE. *Nat Methods* **9**, 591-593 (2012).
12. P. A. Carr *et al.*, Enhanced multiplex genome engineering through co-operative oligonucleotide co-selection. *Nucleic Acids Res.*, (2012).
13. F. van Vliet, B. Silva, M. van Montagu, J. Schell, Transfer of RP4::mu plasmids to *Agrobacterium tumefaciens*. *Plasmid* **1**, 446-455 (1978).
14. J. M. Alonso, A. N. Stepanova, Arabidopsis transformation with large bacterial artificial chromosomes. *Methods Mol Biol* **1062**, 271-283 (2014).
15. V. L. Waters, Conjugation between bacterial and mammalian cells. *Nat.Genet.* **29**, 375-376 (2001).
16. T. Kunik *et al.*, Genetic transformation of HeLa cells by *Agrobacterium*. *Proc Natl Acad Sci U S A* **98**, 1871-1876 (2001).
17. M. Kalkum, R. Eisenbrandt, R. Lurz, E. Lanka, Tying rings for sex. *Trends Microbiol.* **10**, 382-387 (2002).
18. C. Lartigue *et al.*, Genome transplantation in bacteria: changing one species to another. *Science* **317**, 632-638 (2007).
19. D. G. Gibson *et al.*, Complete chemical synthesis, assembly, and cloning of a *Mycoplasma genitalium* genome. *Science* **319**, 1215-1220 (2008).
20. M. A. Algire *et al.*, New selectable marker for manipulating the simple genomes of *Mycoplasma* species. *Antimicrobial agents and chemotherapy* **53**, 4429-4432 (2009).
21. C. Lartigue *et al.*, Creating bacterial strains from genomes that have been cloned and engineered in yeast. *Science* **325**, 1693-1696 (2009).

22. G. A. Benders *et al.*, Cloning whole bacterial genomes in yeast. *Nucleic Acids Res* **38**, 2558-2569 (2010).
23. D. G. Gibson *et al.*, Creation of a bacterial cell controlled by a chemically synthesized genome. *Science* **329**, 52-56 (2010).
24. H. H. Wang, Synthetic genomes for synthetic biology. *J.Mol.Cell Biol.* **2**, 178-179 (2010).
25. C. Tagwerker *et al.*, Sequence analysis of a complete 1.66 Mb Prochlorococcus marinus MED4 genome cloned in yeast. *Nucleic Acids Res* **40**, 10375-10383 (2012).
26. B. J. Karas *et al.*, Direct transfer of whole genomes from bacteria to yeast. *Nat Methods* **10**, 410-412 (2013).
27. C. N. Santos, D. D. Regitsky, Y. Yoshikuni, Implementation of stable and complex biological systems through recombinase-assisted genome engineering. *Nature communications* **4**, 2503 (2013).
28. R. Krishnakumar *et al.*, Simultaneous non-contiguous deletions using large synthetic DNA and site-specific recombinases. *Nucleic Acids Res* **42**, e111 (2014).
29. C. N. Santos, Y. Yoshikuni, Engineering complex biological systems in bacteria through recombinase-assisted genome engineering. *Nature protocols* **9**, 1320-1336 (2014).
30. M. C. Bassalo *et al.*, Rapid and Efficient One-Step Metabolic Pathway Integration in *E. coli*. *ACS synthetic biology* **5**, 561-568 (2016).
31. J. D. Boeke *et al.*, GENOME ENGINEERING. The Genome Project-Write. *Science* **353**, 126-127 (2016).
32. F. J. Isaacs *et al.*, Precise manipulation of chromosomes in vivo enables genome-wide codon replacement. *Science* **333**, 348-353 (2011).
33. B. M. Barton, G. P. Harding, A. J. Zuccarelli, A general method for detecting and sizing large plasmids. *Anal Biochem* **226**, 235-240 (1995).
34. R. A. Meyers, *Molecular biology and biotechnology: a comprehensive desk reference. Physical maps of human chromosomes.*, (John Wiley & Sons, 1995).
35. C. J. Gregg *et al.*, Rational optimization of tolC as a powerful dual selectable marker for genome engineering. *Nucleic Acids Res* **42**, 4779-4790 (2014).
36. T. Conway *et al.*, Unprecedented high-resolution view of bacterial operon architecture revealed by RNA sequencing. *MBio* **5**, e01442-01414 (2014).
37. D. Yu *et al.*, An efficient recombination system for chromosome engineering in *Escherichia coli*. *Proc Natl Acad Sci U S A* **97**, 5978-5983 (2000).
38. E. C. Lee *et al.*, A Highly Efficient *Escherichia coli*-Based Chromosome Engineering System Adapted for Recombinogenic Targeting and Subcloning of BAC DNA. *Genomics* **73**, 56-65 (2001).
39. C. J. Gregg *et al.*, Rational optimization of tolC as a powerful dual selectable marker for genome engineering. *Nucleic Acids Res.*, (2014).
40. Y. Tashiro, H. Fukutomi, K. Terakubo, K. Saito, D. Umeno, A nucleoside kinase as a dual selector for genetic switches and circuits. *Nucleic Acids Res.* **39**, e12 (2011).

41. L. P. Elwell *et al.*, Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U). *Antimicrobial agents and chemotherapy* **31**, 274-280 (1987).
42. V. de Berardinis *et al.*, A complete collection of single-gene deletion mutants of *Acinetobacter baylyi* ADP1. *Mol.Syst.Biol.* **4**, 174 (2008).
43. S. Chakraborty, N. Christoforou, A. Fattahi, R. W. Herzog, K. W. Leong, A robust strategy for negative selection of Cre-loxP recombination-based excision of transgenes in induced pluripotent stem cells. *PLoS One* **8**, e64342 (2013).
44. S. M. Byrne, L. Ortiz, P. Mali, J. Aach, G. M. Church, Multi-kilobase homozygous targeted gene replacement in human induced pluripotent stem cells. *Nucleic Acids Res* **43**, e21 (2015).
45. J. F. Li *et al.*, Multiplex and homologous recombination-mediated genome editing in *Arabidopsis* and *Nicotiana benthamiana* using guide RNA and Cas9. *Nat.Biotechnol.* **31**, 688-691 (2013).
46. A. Chavez *et al.*, Precise Cas9 targeting enables genomic mutation prevention *BioRxiv*, (2016).
47. L. P. Elwell, in *Molecular Genetics of Bacterial Pathogenesis*, V. L. Miller, J. B. Kaper, D. A. Portnoy, R. R. Isberg, Eds. (American Society for Microbiology, Washington, D.C., 1994), chap. 2, pp. 17-42.
48. D. Metzgar *et al.*, *Acinetobacter* sp. ADP1: an ideal model organism for genetic analysis and genome engineering. *Nucleic Acids Res.* **32**, 5780-5790 (2004).